Biophytis: approval for a clinical trial in the USA

(CercleFinance.com) - Biophytis was one of the biggest risers on the Paris market on Thursday morning, after receiving approval to start a clinical trial on obesity in the USA.


At around 11.40am, the share price was up by over 6%, with volumes already more than three times their daily average for the last four trading sessions, compared with a slight rise (+0.4%) in the CAC Mid & Small index.

The biotech company announced this morning that the Food and Drug Administration (FDA) had given the go-ahead for the launch of its phase 2 clinical trial in obesity with BIO101, its lead
drug candidate.

The primary objective of the study is to measure improvement in lower limb muscle strength, as assessed by the knee extension test.

Secondary endpoints will include analysis of mobility (via the six-minute walk test) and body composition (assessment of fat and lean mass).

The idea is to observe a weight loss potentially additional to that obtained with GLP-1 RAs, the star anti-obesity drugs of the moment.

The study is due to start in mid-2024 in the United States, and could be extended to Europe, with preliminary results expected in 2025.

In its press release, Biophytis nevertheless states that it is seeking funding and partnerships to carry out this study.

Copyright (c) 2024 CercleFinance.com. All rights reserved.